Form D — Cadrenal Therapeutics, Inc.
0001213900-25-127129 · filed Dec 31, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $4,396,329
- Reported amount sold
- $4,396,329
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Cadrenal Therapeutics, Inc.
- CIK
- 1937993
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2022
- Address
- 822 A1A NORTH, SUITE 306
PONTE VEDRA, Florida 32082 - Phone
- (904) 300-0701
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
QUANG X. PHAM · Executive OfficerPONTE VEDRA, Florida Find on LinkedIn ↗
-
MATTHEW K. SZOT · Executive OfficerPONTE VEDRA, Florida Find on LinkedIn ↗
-
JEFFREY COLE · Executive OfficerPONTE VEDRA, Florida Find on LinkedIn ↗
-
JAMES J. FERGUSON · Executive OfficerPONTE VEDRA, Florida Find on LinkedIn ↗
-
STEVEN ZELENKOFSKE · DirectorPONTE VEDRA, Florida Find on LinkedIn ↗
-
GLYNN WILSON · DirectorPONTE VEDRA, Florida Find on LinkedIn ↗
-
JOHN R. MURPHY · DirectorPONTE VEDRA, Florida Find on LinkedIn ↗
-
LEE S. GOLDEN · DirectorPONTE VEDRA, Florida Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗